Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- ULH +9.7%, ANRO +9.7%, NIU +3.2%, VNET +2.8%, VFS +1.3%, SAIC +1.2%, OLMA +1%
Other news:
- CTMX +48.7% (Varsetatug Masetecan (EpCAM PROBODY ADC) continues to demonstrate positive data supporting potential as a new treatment option in late-line colorectal cancer)
- GPCR +15.7% (reports positive topline data from the ACCESS clinical program of aleniglipron for the treatment of people living with obesity and/or overweight with at least one weight related co-morbidity)
- NBIS +13.9% (signs new AI infrastructure agreement with Meta)
- ANRO +9.7% (enters into securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing for gross proceeds of approximately $120 mln)
- NBP +9.5% (receives FDA alignment on accelerated approval pathway for givastomig)
- SOC +7% (Secretary of Energy Chris Wright directed Sable Offshore Corp. to restore operations of the Santa Ynez Unit and Santa Ynez Pipeline System to address supply disruption risks caused by California policies that have left the region and U.S. military forces dependent on foreign oil; resumes oil flow as ordered by the federal DPA with expected gross oil rate of 50,000 bbls/d and expects first sales by April 1, 2026)
- HIVE +5.2% (expands Canadian AI data center capacity through BUZZ HPC)
- MU +4.7% (completes acquisition of Taiwan fab site to expand AI memory capacity)
- GLSI +4.3% (announces use of commercially manufactured GP2 in FLAMINGO-01)
- SENS +4.1% (presents first ever real-world evidence of Eversense 365 Presented at ATTD demonstrates sustained performance and positive impact throughout one-year of wear)
- ENLT +3.6% (announces the financial close for the Crimson Orchard Project)
- KRRO +3.5% (files for 7,650,764 share common stock offering by selling shareholders)
- INFQ +3.4% (delivers UK's first operational 100-qubit quantum system)
- STXS +3.2% (files for $100 mln mixed securities shelf offering)
- BNC +3.1% (acknowledges request tied to activist board takeover attempt)
- NESR +2.9% (has secured several, multi-year Cementing contract awards valued at ~ $300 mln)
- VTS +2.3% (announces hedging update and board member transition)
- NEO +2.2% (PanTracer LBx test has received coverage from the Centers for Medicare & Medicaid Services' Molecular Diagnostics Services Program)
- RSKD +1.9% (to repurchase 1 mln Class A ordinary shares from Pitango Venture Capital)
- MEOH +1.8% (OCI Chemicals B.V. has sold 3,331,346 common shares of Methanex Corporation representing approximately 4.3% of the issued and outstanding Shares) GLUE +1.7% (has entered into a supply agreement with Johnson & Johnson (JNJ) to evaluate MRT-2359 in combination with ERLEADA for the treatment of patients with metastatic castration-resistant prostate cancer with androgen receptor mutations in a planned Phase 2 study expected to initiate in the third quarter of 2026)
- IRD +1.4% (files for 7,374,632 share common stock offering by selling shareholders)
- RLAY +1.4% (announces data from Zovegalisib + Fulvestrant at the phase 3 dose of 400mg BID Fed at ESMO targeted anticancer therapies congress 2026)
- HSTM +1.3% (approves new share repurchase program for up to $10.0 mln of common stock)
- OWL +1% (unanimously recommends shareholders reject unsolicited minority offer from Cox and Saba)